Masashi Takano

Summary

Affiliation: National Defense Medical College
Country: Japan

Publications

  1. pmc Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review
    Morikazu Miyamoto
    Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan
    J Gynecol Oncol 24:37-43. 2013
  2. ncbi request reprint UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
    Eur J Gynaecol Oncol 34:120-3. 2013
  3. doi request reprint Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama 359 8513, Japan
    J Obstet Gynaecol Res 39:872-5. 2013
  4. ncbi request reprint Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Eur J Gynaecol Oncol 34:90-3. 2013
  5. pmc Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    J Exp Clin Cancer Res 31:53. 2012
  6. ncbi request reprint Embryonal rhabdomyosarcoma of the uterine corpus in a 76-year-old patient
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, 359 8513, Japan
    Gynecol Oncol 75:490-4. 1999
  7. doi request reprint Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Onkologie 32:595-7. 2009
  8. ncbi request reprint Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
    Eur J Gynaecol Oncol 30:575-8. 2009
  9. doi request reprint The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 19:1353-7. 2009
  10. doi request reprint Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 20:1506-10. 2010

Collaborators

Detail Information

Publications79

  1. pmc Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review
    Morikazu Miyamoto
    Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan
    J Gynecol Oncol 24:37-43. 2013
    ..In the present study, multivariate analysis to compare prognosis of CCC patients with that of SAC was aimed for the patients selected from central pathologic review...
  2. ncbi request reprint UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
    Eur J Gynaecol Oncol 34:120-3. 2013
    ..The aim of the present study was to determine the RD of irinotecan in combination with cisplatin (CPT-P) for individuals with or without UGT1A1 polymorphisms...
  3. doi request reprint Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama 359 8513, Japan
    J Obstet Gynaecol Res 39:872-5. 2013
    ..The progression-free interval of the patient is over 30 months, and she is still receiving the combination therapy without toxicities of more than grade 2...
  4. ncbi request reprint Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Eur J Gynaecol Oncol 34:90-3. 2013
    ..A certain modification of schedule might therefore facilitate the clinical application of the regimen. The authors report two cases that achieved complete response to a weekly administration of bevacizumab and GEMOX...
  5. pmc Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    J Exp Clin Cancer Res 31:53. 2012
    ..In this review article, we discuss the surgical issues for early-staged and advanced CCC including possibility of fertility-sparing surgery, and the chemotherapy for CCC disease...
  6. ncbi request reprint Embryonal rhabdomyosarcoma of the uterine corpus in a 76-year-old patient
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, 359 8513, Japan
    Gynecol Oncol 75:490-4. 1999
    ..Primary embryonal rhabdomyosarcoma of the uterine corpus is an extremely rare tumor. A case of rhabdomyosarcoma originating in the uterine myoma is presented with a review of the literature...
  7. doi request reprint Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Onkologie 32:595-7. 2009
    ..Palliative therapy is usually employed for the treatment of metastatic or relapsed cervical cancer. Many agents including cisplatin have been used for fighting the tumor; however, the gold standard therapy has not yet been confirmed...
  8. ncbi request reprint Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature
    M Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
    Eur J Gynaecol Oncol 30:575-8. 2009
    ..The cases and a review of the literature suggested that residual tumor volume size determines the survival of these patients, and that the tumors show resistance to conventional platinum-based chemotherapy...
  9. doi request reprint The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 19:1353-7. 2009
    ..More effective treatment modality was warranted, especially for CCC cases positive for malignant peritoneal cytology...
  10. doi request reprint Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 20:1506-10. 2010
    ..However, CCC often showed chemo-resistant phenotype, and the effect of adjuvant chemotherapy still remained uncertain...
  11. doi request reprint Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study
    Masashi Takano
    Department of Gynecology, Saitama Cancer Center, Adachi Gun, Japan
    Oncology 76:315-21. 2009
    ..To investigate the effects of UDP-glucuronosyltransferase 1A1 (UGT1A1) *28, *6 and *27 in patients with gynecologic cancer who received chemotherapy with irinotecan and cisplatin...
  12. ncbi request reprint Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3 2, Tokorozawa, Saitama, 359 8513, Japan
    Int J Clin Oncol 12:256-60. 2007
    ..Our aim was to compare progression-free survival (PFS) between patients treated with irinotecan hydrochloride and cisplatin (CPT-P) and those with treated with paclitaxel and carboplatin (TC)...
  13. doi request reprint Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Int J Clin Oncol 16:605-9. 2011
    ..In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial...
  14. ncbi request reprint Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359 8513, Japan
    Oncol Rep 19:1259-64. 2008
    ..03) and that the chemotherapeutic regimen was not a prognostic factor (p=0.43). The present study indicates that we should accomplish complete surgical staging procedures for CCC confined to the ovary...
  15. ncbi request reprint Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama 359 8513, Japan
    Oncol Rep 16:1301-6. 2006
    ..However, this is a limited retrospective study, therefore we recommend that the CPT-P regimen be evaluated in a larger prospective study...
  16. doi request reprint ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Saitama, Japan
    Histopathology 60:1073-83. 2012
    ..2, enhances cell motility by bundling the actin cytoskeleton. We assessed how ACTN4/actinin-4 alterations contribute to the tumorigenesis of ovarian clear-cell adenocarcinomas (CCAs)...
  17. doi request reprint Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 25:122-30. 2012
    ....
  18. doi request reprint Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases
    Yuji Ikeda
    Department of Obstetrics and Gynecology, Ohki Memorial Kikuchi Cancer Center for Women, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 23:355-60. 2013
    ..Here, we evaluated the effect of weekly low-dose administration of GEMOX in combination with bevacizumab (B-GEMOX) for patients with recurrent and refractory ovarian cancers (ROCs)...
  19. doi request reprint Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer
    Ei ichiro Tominaga
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjyuku ku, Tokyo, Japan
    Gynecol Oncol 118:160-6. 2010
    ..The purpose of this study was to identify genes that predict progression-free survival (PFS) in advanced epithelial ovarian cancer (aEOC) receiving standard therapy...
  20. doi request reprint Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 25:615-24. 2012
    ....
  21. doi request reprint Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
    Mod Pathol 22:499-507. 2009
    ..The actinin-4 gene may be a target of the 19q amplicon, acting as a candidate oncogene, and serve as a predictor of poor outcome and tumor chemoresistance in patients with advanced-stage ovarian cancers...
  22. doi request reprint Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 30:431-41. 2011
    ..On the basis of the prognostic impact and interobserver reproducibility, the present binary classification system for CCAs was deemed to be highly superior to the compared conventional histologic grading system...
  23. ncbi request reprint The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
    Tsunekazu Kita
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Gynecol Oncol 92:813-8. 2004
    ..The purpose of this study was to reconfirm the effect of weekly paclitaxel in more number of cases...
  24. doi request reprint Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 30:129-38. 2011
    ..These results suggest that the 2 tested grading systems have limited value for the prognostication of patients with clear cell adenocarcinoma, and that a more effective grading system for this tumor may be required...
  25. doi request reprint Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary
    Kosuke Miyai
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 29:321-7. 2010
    ..These data suggest that ovarian endometrioid adenocarcinoma, even when small in size, can give rise to a massive undifferentiated carcinoma filling the peritoneal cavity...
  26. doi request reprint Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group
    Yoh Watanabe
    Department of Obstetrics and Gynecology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osakasayama, Osaka 589 8511, Japan
    Gynecol Oncol 115:456-9. 2009
    ..To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG)...
  27. doi request reprint Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Japan
    Int J Gynecol Pathol 31:116-24. 2012
    ..The proposed grouping system could divide patients with CCA into 3 subgroups with distinct prognostic indications, providing a 3-tier histological grading system for ovarian CCA...
  28. ncbi request reprint Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers
    Tomoko Goto
    Department of Obstetrics and Gynecology, Saitama Medical College, Iruma gun, Saitama 350 0495, Japan
    Oncol Rep 15:1265-71. 2006
    ..004). RhoGDI expression proved to be a predictive marker of paclitaxel resistance not only in paclitaxel-resistant cell lines, but also in clinical samples...
  29. doi request reprint Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
    Kazuya Kudoh
    Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama, Japan
    Gynecol Oncol 122:233-7. 2011
    ..We have conducted a preliminary study to investigate effects of combination of bevacizumab and PLD for heavily pretreated patients with ROC...
  30. doi request reprint Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers
    Tomoko Goto
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Cancer 21:263-8. 2011
    ..The purpose of this study was to explore the potential survival benefit of SCS in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers...
  31. doi request reprint Identification of potential serum markers for endometrial cancer using protein expression profiling
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, 359 8513, Japan
    J Cancer Res Clin Oncol 136:475-81. 2010
    ..Screening method of endometrial cancer (EC) has not been established yet. Our study was to explore serum biomarkers of EC patients using surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS)...
  32. ncbi request reprint Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study
    Satoshi Takakura
    Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
    Int J Gynecol Cancer 20:240-7. 2010
    ..Combination chemotherapy with irinotecan hydrochloride plus cisplatin has been reported to be effective for primary and recurrent or resistant CCC. We compared these 2 combinations in patients with CCC...
  33. doi request reprint Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Saitama, Japan
    Mod Pathol 24:1146-55. 2011
    ..MET could serve as a biomarker for the prognostication of patients with clear-cell adenocarcinoma and tumor progression, and has potential as a novel therapeutic target for this carcinoma...
  34. doi request reprint Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defence Medical College, Tokorozawa, Saitama, Japan
    Histopathology 56:740-9. 2010
    ..To identify the key cell-cycle dysregulations in the development of endometriosis-associated ovarian clear cell adenocarcinoma (CCA)...
  35. ncbi request reprint Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Mod Pathol 21:115-24. 2008
    ....
  36. doi request reprint Aberrant expression of p27(Kip1)-interacting cell-cycle regulatory proteins in ovarian clear cell carcinomas and their precursors with special consideration of two distinct multistage clear cell carcinogenetic pathways
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Virchows Arch 455:413-22. 2009
    ....
  37. ncbi request reprint Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer
    Shizuo Machida
    Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan
    Oncology 65:102-7. 2003
    ..We performed a phase I clinical study to evaluate combination chemotherapy with irinotecan hydrochloride (CPT-11) and nedaplatin (CPT-11/nedaplatin) for cervical cancer...
  38. doi request reprint Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas
    Sadako Nishimura
    Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka, Japan
    Int J Gynecol Cancer 20:220-6. 2010
    ..In this study, we generated a polyclonal antiserum to HIG2 to explore the use of HIG2 as a predictive biomarker in EOC. In addition, HIG2 expression was evaluated in uterine endometrial and renal CCCs...
  39. doi request reprint Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma?
    Tatsuyuki Chiyoda
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
    Genes Chromosomes Cancer 51:229-39. 2012
    ..TGF-beta signaling is activated in CS and chromosomal gains at 19q13, which includes the TGFB1 locus, suggest that this may contribute to high expression of TGF-beta and thereby EMT phenotype of CS...
  40. doi request reprint PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defence Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    J Pathol 225:189-94. 2011
    ..A specific kinase inhibitor to mutated PIK3CA may potentially be an effective therapeutic reagent against these carcinomas...
  41. pmc Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19 1 Uchimaru, Morioka 020 8505, Japan
    Cancer Chemother Pharmacol 71:657-62. 2013
    ..There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC)...
  42. ncbi request reprint Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan
    Anticancer Res 22:1833-8. 2002
    ..In this phase I trial, 80 mg/m2/week of paclitaxel was recommended as the phase II dose for outpatients...
  43. doi request reprint PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    Virchows Arch 460:77-87. 2012
    ..013). PIK3CA gene mutations and ARID1A immunohistochemistry lacked prognostic significance. These data further support the idea that these molecular alterations occur as very early events during tumor development of ovarian CCA...
  44. ncbi request reprint [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement]
    Masashi Takano
    Dept of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Gan To Kagaku Ryoho 35:1981-4. 2008
    ..Therefore, we do recommend that special cautions are required for the bevacizumab- based chemotherapy, especially severely pretreated ovarian cancer patients...
  45. doi request reprint An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, 359 8513, Japan
    Virchows Arch 455:261-70. 2009
    ..These data further support the presence of two distinct carcinogenic pathways to ovarian clear-cell adenocarcinoma; the allelic status of the 3p, 5q, and 11q loci may provide a means to identify the precursor lesions of these carcinomas...
  46. ncbi request reprint [The impact of systematic lymphadenectomy for early-stage ovarian carcinomas]
    Morikazu Miyamoto
    Dept of Obstetrics and Gynecology, National Defense Medical College Hospital, Japan
    Gan To Kagaku Ryoho 38:1837-40. 2011
    ..473(95%CI, 0. 235-0. 951; p=0. 036). The present study suggested the systematic lymphadenectomy had a significant therapeutic effect on pT1 stage ovarian cancers...
  47. doi request reprint Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1α, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma
    Masafumi Kato
    Departments of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Int J Gynecol Pathol 31:254-63. 2012
    ..Expressions of p-mTOR, HIF-1α, and Glut1 have already been evident in the putative precursor lesions of CCA, and these alterations cumulatively occur in the development of ovarian CCA...
  48. ncbi request reprint Treatment options in the management of ovarian cancer
    Yoshihiro Kikuchi
    Department of Obstetrics and Gynecology, National Defence Medical College, Tokorozawa, Saitama 359 8513, Japan
    Expert Opin Pharmacother 6:743-54. 2005
    ..Cautious optimism should prevail for all investigators involved in translating these exciting new biological findings into new pharmacological agents for treatment of cancer...
  49. ncbi request reprint Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients
    Kenji Yamamoto
    Department of Obstetrics and Gynecology, Shounan Kamakura General Hospital, Kamakura, Kanagawa, Japan
    Curr Med Chem 11:425-8. 2004
    ..Side effects by weekly T were mild and tolerable despite of long term treatment. In addition, weekly T can be safely used in outpatient setting and even in patients with poor performance status (PS), and warrant long time to progression...
  50. doi request reprint p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer
    Tomoko Goto
    Department of Gynaecologic Oncology, Saitama Medical University International Medical Centre Comprehensive Cancer Centre, 1397 1 Yamane, Hidaka, Saitama, Japan
    Int J Cancer 125:339-44. 2009
    ..Our data suggest that p16INK4a expression in cytology of ascites is a candidate marker in prediction of the primary response to chemotherapy and prognosis...
  51. ncbi request reprint Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama 359 8513, Japan
    Oncol Rep 12:1177-82. 2004
    ..01). We concluded that the cytoplasmic overexpression of MUC1 might be an indicator of resistance to platinum-based chemotherapy and a prognostic marker in ovarian cancer...
  52. doi request reprint High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway
    Kosuke Yoshihara
    Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    Clin Cancer Res 18:1374-85. 2012
    ..Our aim was to establish a novel risk classification system based on a gene expression signature for predicting overall survival, leading to suggesting novel therapeutic strategies for high-risk patients...
  53. doi request reprint Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection
    Toyomi Satoh
    Department of Obstetrics and Gynecology, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba, Ibaraki 305 8575, Japan
    J Clin Oncol 28:1727-32. 2010
    ..The objective of this study was to assess clinical outcomes and fertility in patients treated conservatively for unilateral stage I invasive epithelial ovarian cancer (EOC)...
  54. ncbi request reprint Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama, Japan
    Mod Pathol 20:1278-85. 2007
    ..Accumulation of actinin-4 in the cytoplasm may be related to a higher propensity for tumor invasiveness and metastasis, probably by enhancing cell motility, and could be a novel prognostic indicator for patients with ovarian carcinomas...
  55. ncbi request reprint Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey
    Yoh Watanabe
    Department of Obstetrics and Gynecology, Kinki University School of Medicine, 377 2 Ohno Higashi, Osakasayama, Osaka 589 8511, and National Hospital Organization Kobe Medical Center, Japan
    Gynecol Oncol 105:325-8. 2007
    ..We investigated the current status of surgical procedures for endometrial carcinoma in Japan by surveying members of the Japan Gynecologic Oncology Group (JGOG)...
  56. ncbi request reprint Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance
    Kazushige Kiguchi
    Department of Obstetrics and Gynecology, St Marianna University School of Medicine, 2 16 1 Sugao, Miyamae ku, Kawasaki, Kanagawa 216 8511, Japan
    Cancer Sci 97:1321-6. 2006
    ....
  57. doi request reprint Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan
    J Obstet Gynaecol Res 39:1354-8. 2013
    ..The findings in this patient indicate that CPT-11 should be administered with great care, even at a dose of 60 mg/m², in patients receiving combined therapy with CPT-11 and NDP who are compound heterozygous for UGT1A1*6 and UGT1A1*28...
  58. ncbi request reprint Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330)
    Hiroshi Tsubamoto
    Department of Obstetrics and Gynecology, Hyogo College of Medicine, Mukogawa 1 1, Nishinomiya, Hyogo 663 8501, Japan
    Anticancer Res 33:1073-9. 2013
    ..A multicenter phase II trial was conducted to evaluate the efficacy and toxicity of irinotecan plus carboplatin chemotherapy in patients with epithelial ovarian cancer (EOC)...
  59. ncbi request reprint Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary
    Hiroshi Tsuda
    Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Int J Gynecol Cancer 20:794-7. 2010
    ....
  60. ncbi request reprint Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, 359 8513, Japan
    Gynecol Oncol 91:444-8. 2003
    ..A case of hepatoid adenocarcinoma in malignant mixed Mullerian tumor of the uterus is presented with a review of the literature...
  61. ncbi request reprint Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia
    Tomoko Goto
    Department of Obstetrics and Gynecology, Saitama Medical College, 38 Morohongo, Iruma gun, Saitama 350 0495, Japan
    Oncol Rep 15:387-91. 2006
    ..Thus, expression of PIK3CA was observed in liquid-based cytology in CIN lesions, which suggested its diagnostic significance in addition to the use of routine cervical cancer smear and the HPV screening program...
  62. doi request reprint Case of peptide-YY-producing strumal carcinoid of the ovary: a case report and review
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan
    J Obstet Gynaecol Res 38:1266-70. 2012
    ..The clinical course of this case supports the previously recognized correlation between peptide-YY-producing ovarian carcinoid and constipation...
  63. ncbi request reprint Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma
    Naoki Sasaki
    Department of Gynecology and Obstetrics, National Defense Medical College, Saitama, Japan
    J Obstet Gynaecol Res 33:17-23. 2007
    ..To investigate the effect of HER-2/neu protein overexpression on chemoresistance and prognosis in patients with epithelial ovarian carcinoma...
  64. ncbi request reprint Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama 359 8513, Japan
    Am J Surg Pathol 31:999-1006. 2007
    ..These results suggest that CCAF besides endometriosis is associated with the development of CCA, and that the CCAF(+) group may be a distinct subgroup of CCA with less aggressive biologic behavior...
  65. ncbi request reprint An extremely rare case of adenoma malignum with large cystic tumor which resulted in urinary obstruction
    Tomoko Gotoh
    Department of Obstetrics and Gynecology, National Defense Medical College, Namiki 3 2, Tokorozawa, Saitama 359 8513, Japan
    Gynecol Oncol 84:339-43. 2002
    ..Adenoma malignum is a rare variant of uterine cervical adenocarcinoma. In this report, we present an extremely rare case of adenoma malignum with large cystic lesions (diameter of more than 10 cm) which elicited urinary obstruction...
  66. ncbi request reprint Successful management of cervical pregnancy by selective uterine artery embolization: a case report
    Masashi Takano
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan
    J Reprod Med 49:986-8. 2004
    ..Cervical pregnancy is potentially associated with life-threatening hemorrhage and often requires hysterectomy to stop the bleeding. Conservative management is becoming more common as treatment of cervical pregnancy...
  67. ncbi request reprint Transcriptional role of FOXO1 in drug resistance through antioxidant defense systems
    Tomoko Goto
    Department of Obstetrics and Gynecology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama 359 8513, Japan
    Adv Exp Med Biol 665:171-9. 2009
    ....
  68. ncbi request reprint Ovarian metastasis in carcinoma of the uterine cervix
    Muneaki Shimada
    Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36 1 Nishimachi Yonago 683 8504, Japan
    Gynecol Oncol 101:234-7. 2006
    ..The present study was conducted to determine the frequency and clinicopathological features of ovarian metastasis in a large population of patients with stage Ib-IIb cervical cancer...
  69. ncbi request reprint Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma
    Morio Sawada
    Department of Gynecology, National Cancer Center Hospital, Tokyo, and Department of Pathology II, National Defense Medical College, Tokorozawa
    Cancer Sci 94:986-91. 2003
    ..Structural and/or numerical alterations of chromosomes might be in part involved in EGFR and/or HER-2 overexpression in this tumor type...
  70. ncbi request reprint PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy
    Yasunobu Kanamori
    Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36 1 Nishimachi, Yonago 683 8504, Japan
    Int J Cancer 100:686-9. 2002
    ..PTEN-positive staining was a significant prognostic indicator of favorable survival for patients with advanced endometrial carcinoma who underwent postoperative chemotherapy...
  71. ncbi request reprint Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma
    Sohei Yamamoto
    Department of Basic Pathology, National Defense Medical College, 3 2 Namiki, Tokorozawa, Saitama 359 8513, Japan
    Virchows Arch 451:27-35. 2007
    ..003), Ki-67 LI (P = 0.012), Bcl-2 expression (P = 0.003), and poorer patient outcome (5-year survival, 36.5 vs 63.8%, P = 0.008 by log-rank test). The WT1 protein may be an accelerator of the progression of OSA...
  72. ncbi request reprint Inhibitory effects of bisphosphonates on the proliferation of human ovarian cancer cell lines and the mechanism
    Junko Hirata
    Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Med Chem 2:223-6. 2006
    ..KFr 13 cells among ovarian cancer cell lines used was the most sensitive to pamidronate and the caspase 3 activity was markedly stimulated by treatment with pamidronate, suggesting induction of apoptosis...
  73. ncbi request reprint [The efficacy of Shakuyaku-Kanzo-to for peripheral nerve dysfunction in paclitaxel combination chemotherapy for epithelial ovarian carcinoma]
    Kazuyuki Fujii
    Dept of Obstetrics and Gynecology, National Defense Medical College
    Gan To Kagaku Ryoho 31:1537-40. 2004
    ..We suggested that Paclitaxel combination chemotherapy with Shakuyaku-Kanzo-to taken orally is a more safe and tolerable way to reduce pain in epithelial ovarian carcinoma...
  74. ncbi request reprint [Relationship between overexpression of HER-2/neu protein and prognosis in epithelial ovarian cancer]
    Naoki Sasaki
    Department of Gynecology and Obstetrics, National Defense Medical College
    Nihon Rinsho 62:582-6. 2004
  75. ncbi request reprint [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma]
    Kazuyuki Fujii
    Dept of Obstetrics and Gynecology, National Defense Medical College
    Gan To Kagaku Ryoho 31:2141-4. 2004
    ..But we have many chemoresistant cases, and we examined the efficacy of weekly, single-agent, paclitaxel administration...
  76. ncbi request reprint Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling
    Zachariah E Selvanayagam
    Department of Pediatrics, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    Cancer Genet Cytogenet 154:63-6. 2004
    ..Hence, gene expression profiling by means of DNA microarray may be applied diagnostically for predicting treatment response in ovarian cancer...
  77. ncbi request reprint Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers
    Toru Hachisuga
    Department of Obstetrics and Gynecology, Fukuoka University School of Medicine, 45 1, 7 chome, Nanakuma, Jonan ku, Fukuoka 814 0180, Japan
    Gynecol Oncol 95:139-44. 2004
    ..The aim of this study was to describe the clinicopathologic features and prognosis of endometrial cancer patients diagnosed during or after tamoxifen treatment for breast cancer...
  78. ncbi request reprint Extracellular cAMP-dependent protein kinase (ECPKA) in melanoma
    Tsunekazu Kita
    Department of Surgery, School of Public Health Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA
    Cancer Lett 208:187-91. 2004
    ..Most importantly, surgical removal of melanoma causes a precipitous decrease in ECPKA activity in the sera of patients, suggesting that ECPKA may be a novel predictive marker in melanoma...
  79. ncbi request reprint Application of expression genomics for predicting treatment response in cancer
    Khew Voon Chin
    Department of Medicine, Medical University of Ohio at Toledo, Toledo, Ohio 43614 5809, USA
    Ann N Y Acad Sci 1058:186-95. 2005
    ..We envision that transcription profiling of the cancer genomes ultimately will not only reveal how altered gene expression results in resistance to treatment, but also be exploited for predicting and personalizing cancer therapy...